Adienne is a private, integrated biopharma group founded in 2008, specializing in orphan drugs and biosimilars. The company operates with a dual headquarters structure in Switzerland and Italy, leveraging its manufacturing capabilities to develop therapies for niche, high-need therapeutic areas. Its pipeline includes marketed, clinical, and preclinical assets, positioning it in the commercial stage with a focus on rare diseases.
Orphan Diseases
Technology Platform
Integrated biopharmaceutical development and GMP manufacturing platform for antibodies, biologics, and biosimilars.
Funding History
3
Total raised:$90M
Series B$40MUndisclosed
Series A$25MUndisclosed
Series A$25MFondo Italiano d'Investimento
Opportunities
The growing global orphan drug market, supported by favorable regulations and pricing, offers a significant growth avenue.
Additionally, the biosimilars market provides a substantial opportunity to leverage existing biologics manufacturing expertise for developing cost-effective alternatives to off-patent biologics.
Risk Factors
Key risks include clinical trial failures for pipeline candidates, challenges in commercializing niche orphan drugs, and the financial constraints typical of a private biopharma company.
Operational risks related to maintaining complex biologics manufacturing are also present.
Competitive Landscape
Adienne competes in the specialized orphan drug and biosimilars spaces. Competition includes large pharma companies with orphan drug divisions, pure-play rare disease biotechs, and established biosimilar developers. Its integrated manufacturing model provides a differentiation point against virtual or asset-light biotechs.
